Sort
10,766 grants matching “checkpoint inhibitor”
Project 3. Overcoming Melanoma Treatment Resistance with Cytokine Immunotherapy
$414,525Aaron Michael Ring · Yale University · P50 · FY2024 · CA
Project 2. Harnessing Epigenetic Regulation of Endogenous Retroelements in Melanoma
$414,525Qin Yan · Yale University · P50 · FY2024 · CA
LILRB modulates tumor microenvironment and promotes tumor progression
$414,496Shu-Hsia Chen · Methodist Hospital Research Institute · R01 · FY2022 · CA
Arming Oncolytic HSV Vectors to Induce Anti-GBM Immune Responses in Syngeneic Mice
$414,488Joseph C. Glorioso · University Of Pittsburgh At Pittsburgh · R01 · FY2018 · CA
A Mouse Model to Assess Long Term Immunotherapy-related Adverse Effects in Children
$414,188Yin Wang · University Of Maryland Baltimore · R01 · FY2021 · CA
Checkpoints of TNF Gene Regulation
$414,000Anne Goldfeld · Immune Disease Institute, Inc. · R01 · FY2011 · GM
Investigating a Novel Inhibitory Receptor in Regulating CAR-T Cell Persistence and Function
$413,971Li Lily Wang · Cleveland Clinic Lerner Com-Cwru · R21 · FY2024 · CA
Project 3: Chronic interferon and bile acid signaling as drivers of immunosuppression in age-related liver cancer
$413,965Susan M Kaech · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2024 · AG
Project 2: Cytoplasmic chromatin fragments (CCF) as a driver of liver cancer and target for intervention during aging
$413,965Peter D. Adams · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2024 · AG
Platelets-Mediated Delivery of Checkpoint Inhibitors for Post-Surgical Cancer Immunotherapy
$413,953Song Li · University Of California Los Angeles · R01 · FY2021 · CA
Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer
$413,920Jonathan Maybaum · University Of Michigan At Ann Arbor · R01 · FY2010 · CA
Project 1: Targeting immunotherapy-induced resistance with DC vaccination and PD-1/CSF-1R inhibition
$413,778Robert M Prins · University Of California Los Angeles · P50 · FY2024 · CA
Role of MetAP-2 in Angiogenesis and Wnt Signaling
$413,750Craig M Crews · Yale University · R01 · FY2009 · CA
Mre11-Dependent DNA Damage Responses in Breast Cancer Pathogenesis
$413,651Gaorav P. Gupta · Univ Of North Carolina Chapel Hill · R37 · FY2023 · CA
Targeting exosomal PDL1 to improve immunotherapy
$413,618Wei Guo · Wistar Institute · P50 · FY2023 · CA
E3 ligase mediated control of Foxp3 expression and immune suppression-mechanisms and potential as immunotherapeutic target
$413,515Drew M. Pardoll · Johns Hopkins University · R01 · FY2021 · AI
E3 ligase mediated control of Foxp3 expression and immune suppression-mechanisms and potential as immunotherapeutic target
$413,515Drew M. Pardoll · Johns Hopkins University · R01 · FY2019 · AI
E3 ligase mediated control of Foxp3 expression and immune suppression-mechanisms and potential as immunotherapeutic target
$413,515Drew M. Pardoll · Johns Hopkins University · R01 · FY2020 · AI
Role of microbiota in therapy to ovarian cancer
$413,353Troy D Randall · University Of Alabama At Birmingham · R01 · FY2019 · CA
Project 4: Interrogating and harnessing age-related IFN signaling and innate immunity in HCC prevention and therapy
$413,341Gen-Sheng Feng · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2022 · AG
HSP90 AS A TARGET FOR MECHANISM-BASED THERAPY FOR CASTRATION-RESISTANT PROSTATE C
$413,330Neal Rosen · Sloan-Kettering Inst Can Research · P50 · FY2007 · CA
Discoidin Domain Receptor Tyrosine Kinase 2 in bladder cancer progression
$413,325Dan Theodorescu · Cedars-Sinai Medical Center · R01 · FY2021 · CA
Discoidin Domain Receptor Tyrosine Kinase 2 in bladder cancer progression
$413,325Dan Theodorescu · Cedars-Sinai Medical Center · R01 · FY2023 · CA
Therapeutic Targeting of Breast Cancer Tumor Initiating Cells
$413,297Charles M Perou · Univ Of North Carolina Chapel Hill · R01 · FY2021 · CA
Therapeutic Targeting of Breast Cancer Tumor Initiating Cells
$413,297Charles M Perou · Univ Of North Carolina Chapel Hill · R01 · FY2025 · CA